SSG
PPH icon

Summit Securities Group’s VanEck Pharmaceutical ETF PPH Stock Holding History

Summit Securities Group’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200
Closed -$16K – 1177
2022
Q1 		$16K Buy
+200
New +$15.3K ﹤0.01% 757

Other funds holding PPH

PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NC
Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return
NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Summit Securities Group's PPH Position: Q2 2022 in Review

Summit Securities Group sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2022, closing a stake of 200 shares — an estimated $16K sold.

Summit Securities Group first reported a position in PPH in Q1 2022 and held it in 1 quarter. The position peaked at $16K in Q1 2022. 91 funds tracked by Wall St. Rank hold PPH as of Q2 2022.

  • Summit Securities Group reported no remaining VanEck Pharmaceutical ETF position as of Q2 2022 after selling out during the quarter.
  • Summit Securities Group sold 200 VanEck Pharmaceutical ETF shares in Q2 2022, an estimated $16K.
  • Summit Securities Group first reported a position in VanEck Pharmaceutical ETF in Q1 2022 and held it in 1 quarter.
  • Summit Securities Group's VanEck Pharmaceutical ETF position peaked at $16K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2022.

Based on Summit Securities Group's 13F filing for Q2 2022, filed 2 Aug 2022.